Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 282

1.

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P.

J Transl Med. 2014 May 7;12(1):116. doi: 10.1186/1479-5876-12-116.

PMID:
24885479
[PubMed - in process]
Free PMC Article
2.

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A.

Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4.

PMID:
24877084
[PubMed - in process]
Free PMC Article
3.

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.

Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V.

J Neurooncol. 2014 May;118(1):109-16. doi: 10.1007/s11060-014-1400-y. Epub 2014 Feb 16.

PMID:
24532241
[PubMed - in process]
Free PMC Article
4.

Targeting bone metastatic cancer: Role of the mTOR pathway.

Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D.

Biochim Biophys Acta. 2014 Apr;1845(2):248-54. doi: 10.1016/j.bbcan.2014.01.009. Epub 2014 Feb 5. Review.

PMID:
24508774
[PubMed - indexed for MEDLINE]
5.

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.

Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M.

Cancer Invest. 2014 May;32(4):144-9. doi: 10.3109/07357907.2014.885984. Epub 2014 Jan 31.

PMID:
24484235
[PubMed - indexed for MEDLINE]
6.

KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.

Barone C, Pinto C, Normanno N, Capussotti L, Cognetti F, Falcone A, Mantovani L.

PLoS One. 2014 Jan 20;9(1):e85897. doi: 10.1371/journal.pone.0085897. eCollection 2014.

PMID:
24465771
[PubMed - in process]
Free PMC Article
7.

Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC.

Ciuffreda L, Incani UC, Steelman LS, Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari S, Cognetti F, McCubrey JA, Milella M.

Curr Pharm Des. 2014;20(24):3944-57.

PMID:
24138714
[PubMed - in process]
8.

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.

Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M.

Expert Opin Drug Discov. 2013 Nov;8(11):1381-97. doi: 10.1517/17460441.2013.843523. Epub 2013 Oct 3.

PMID:
24088065
[PubMed - in process]
9.

Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.

Cardillo I, Spugnini EP, Galluzzo P, Contestabile M, Dell'Anna ML, Picardo M, Crispi S, Calogero RA, Piccolo MT, Arigoni M, Cantarella D, Boccellino M, Quagliuolo L, Ferretti G, Carlini P, Felici A, Boccardo F, Cognetti F, Baldi A.

Future Oncol. 2013 Sep;9(9):1375-88. doi: 10.2217/fon.13.99.

PMID:
23980684
[PubMed - indexed for MEDLINE]
10.

Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.

Clavarezza M, Bordonaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, Cognetti F, Olmeo NA, Carrozza F, Bruzzi P, Del Mastro L; Gruppo Italiano Mammella.

Oncologist. 2013;18(8):924-5. doi: 10.1634/theoncologist.2013-0222. Epub 2013 Aug 12. Erratum in: Oncologist. 2013;18(10):1149.

PMID:
23939283
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M.

World J Gastroenterol. 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511.

PMID:
23901226
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.

Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH Jr, Tassell V, Huang X, Paolini J, Kern KA, Romieu G.

J Clin Oncol. 2013 Aug 10;31(23):2870-8. doi: 10.1200/JCO.2012.43.3391. Epub 2013 Jul 15.

PMID:
23857972
[PubMed - indexed for MEDLINE]
13.

Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.

Massari F, Bria E, Maines F, Milella M, Giannarelli D, Cognetti F, Pappagallo G, Tortora G, Porta C.

Clin Genitourin Cancer. 2013 Dec;11(4):471-6. doi: 10.1016/j.clgc.2013.04.018. Epub 2013 Jun 28.

PMID:
23816527
[PubMed - in process]
14.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.

Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E.

Clinicoecon Outcomes Res. 2013 Apr 11;5:125-35. doi: 10.2147/CEOR.S41850. Print 2013.

PMID:
23610525
[PubMed]
Free PMC Article
15.

Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.

Pacetti U, Veltri E, Fattoruso SI, Cardillo FD, Evangelista S, Cognetti F, Fabi A.

Anticancer Res. 2013 Apr;33(4):1721-4.

PMID:
23564822
[PubMed - indexed for MEDLINE]
16.

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.

Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, Cognetti F.

BMC Cancer. 2013 Mar 28;13:164. doi: 10.1186/1471-2407-13-164.

PMID:
23537313
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.

Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, Gori S, Botti C, Malaguti P, Cognetti F, Mottolese M.

Expert Opin Pharmacother. 2013 Apr;14(6):699-706. doi: 10.1517/14656566.2013.779672. Epub 2013 Mar 9.

PMID:
23472669
[PubMed - indexed for MEDLINE]
18.

The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.

Malaguti P, Vari S, Cognetti F, Fabi A.

Anticancer Res. 2013 Jan;33(1):21-8. Review.

PMID:
23267124
[PubMed - indexed for MEDLINE]
19.

Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.

Felici A, Bria E, Tortora G, Cognetti F, Milella M.

Expert Rev Anticancer Ther. 2012 Dec;12(12):1545-57. doi: 10.1586/era.12.149. Review.

PMID:
23253221
[PubMed - indexed for MEDLINE]
20.

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).

Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, McIntosh S, Nathan F, Pemberton K, Baumann K.

Gynecol Oncol. 2013 Jul;130(1):31-7. doi: 10.1016/j.ygyno.2012.12.004. Epub 2012 Dec 9.

PMID:
23234805
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk